Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $4.04M | — | $1.00M | — | $410K |
| Operating income | -$10.9M | -$13.0M | -$15.6M | -$14.0M | -$14.2M | -$10.2M | -$14.6M | -$9.90M | -$12.7M | -$13.3M |
| Operating margin | — | — | — | — | — | -253.0% | — | -990.0% | — | -3242.5% |
| Net income | -$10.9M | -$11.2M | -$14.7M | -$12.9M | -$13.9M | -$10.1M | -$14.1M | -$8.57M | -$11.0M | -$12.0M |
| Net margin | — | — | — | — | — | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (diluted) | -$0.33 | -$0.32 | -$0.36 | -$0.30 | -$0.31 | -$0.21 | -$0.29 | -$0.17 | -$0.23 | -$0.24 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.55M | -$6.92M | -$9.11M | -$9.12M | -$10.8M | -$9.38M | -$12.9M | -$7.43M | -$10.6M | -$9.81M |
| Capital expenditures | $84.5K | — | $10.2K | $11.3K | $36.5K | $28.7K | $5.01K | $21.3K | $895.00 | $2.90K |
| Free cash flow | -$6.63M | — | -$9.12M | -$9.14M | -$10.9M | -$9.41M | -$12.9M | -$7.45M | -$10.6M | -$9.81M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.1M | $28.0M | $62.3M | $63.8M | $60.0M | $71.4M | $18.5M | $51.0M | $40.4M | $30.8M |
| Total assets | $39.8M | $43.4M | $77.2M | $79.2M | $75.4M | $87.4M | $74.2M | $66.3M | $55.9M | $45.6M |
| Total liabilities | $5.28M | $4.78M | $4.12M | $4.31M | $4.09M | $3.73M | $3.91M | $3.89M | $3.37M | $4.02M |
| Shareholders' equity | $34.5M | $38.6M | $73.1M | $74.9M | $71.3M | $83.7M | $70.2M | $62.4M | $52.5M | $41.6M |
| Retained earnings | -$330M | -$341M | -$356M | -$369M | -$383M | -$393M | -$407M | -$416M | -$427M | -$439M |
| Shares (wtd avg diluted) | 34.5M | 36.5M | 42.1M | 43.9M | 45.0M | 48.6M | 49.0M | 49.0M | 49.0M | 49.1M |
Every figure is extracted from MEDICINOVA INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.